Anaconda Biomed key facts
as of Oct 2026- Developer of intravascular catheter-based medical devices designed to enable mechanical thrombectomy for stroke treatment.
- Anaconda Biomed is valued at approximately $108.1M as of Oct 2026 (last reported valuation).
- It has raised $50.6M; the latest was Later Stage VC in Jan 2025.
- Notable investors include INNVIERTE SICC, Omega Funds, Asabys Partners, EIT Health, Frédéric Picq — 10 tracked in total.
- Status: Privately Held (backing).
Anaconda Biomed's last reported valuation, Dec 2019. Nothing priced has surfaced since.
- ·Watch Anaconda Biomed: the Monday email on marks, rounds and moves
Anaconda Biomed funding rounds
No funding rounds for Anaconda Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Anaconda Biomed valuation
Anaconda Biomed's last reported valuation was $108 million in Dec 2019. No priced round, secondary trade or fund mark has surfaced since.
Anaconda Biomed investors
10 investors are on record for Anaconda Biomed, including INNVIERTE SICC, Omega Funds, Asabys Partners and EIT Health.
About Anaconda Biomed
Developer of intravascular catheter-based medical devices designed to enable mechanical thrombectomy for stroke treatment. The company's platform provides funnel catheters with flow restriction, suction force optimization, and clot retrieval support, enabling healthcare professionals to safely remove clots, reduce embolization risk, improve navigation in neurovascular procedures, and enhance treatment outcomes in acute ischemic stroke cases.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2015
- Employees
- 45
- Website
- anaconda.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.